By Adrian Burton , Special to DG News LISBON, PORTUGAL — May 15, 2002 — Teriparatide increases vertebral bone mineral density (vBMD) in men with osteoporosis, irrespective of their age, previous fracture history, sex steroid levels, and no matter whether they smoked or drank. That finding was presented at the International Osteoporosis Foundation’s World Congress on Osteoporosis. “Secondary causes such as drinking, smoking and low testosterone levels probably cause osteoporosis in about one half to two thirds of cases in men,” explained Eric Orwoll, Prof. of Medicine at the Oregon Health and Science University, Portland, Oregon. “We wanted to know if teriparatide would be useful in these different situations.” The study subjects in this double-blind clinical trial were 437 osteoporotic adult men (mean age 50 years; range from the 4th to 9th decade of life) with spine or hip BMD greater than two standard deviations below that of the mean for young adult males. These men were randomized to follow either a regimen of once-daily self-injected placebo, 20 microg of teriparatide, or 40 microg teriparatide for 11 months. All groups also received supplemental calcium (1000 mg) and vitamin D (400 – 1200 IU).
סל התרופות כמו אקמול לחולה סרטן/ מאמר אורח מאת ד”ר אודי פרישמן
אין תגובות06/01/2020
מדי שנה רועשת וגועשת התקשורת סביב סל התרופות, מה ייכנס
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!